2017
ASSOCIATION BETWEEN THE VITREOMACULAR INTERFACE AND OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS IN WET AGE-RELATED MACULAR DEGENERATION
Ashraf M, Souka A, Adelman RA. ASSOCIATION BETWEEN THE VITREOMACULAR INTERFACE AND OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS IN WET AGE-RELATED MACULAR DEGENERATION. Retina 2017, 37: 1738-1745. PMID: 28005632, DOI: 10.1097/iae.0000000000001423.Peer-Reviewed Original ResearchConceptsType 1 choroidal neovascularizationChoroidal thicknessChoroidal neovascularizationWet AMDVitreomacular adhesionDry AMDVitreomacular interfaceMacular degenerationRetrospective observational cross-sectional studyOptical coherence tomography examinationObservational cross-sectional studyAge-related macular degenerationType of CNVPaired-eye studyMean choroidal thicknessCross-sectional studySignificant differencesOptical coherence tomographyWet AgeSubgroup analysisTomography examinationHeidelberg SpectralisPatientsCoherence tomographyDegeneration characteristic
2016
Hyperacuity Exam Screens for Choroidal Neovascularization in Age-Related Macular Degeneration on a Mobile Device.
Chen JS, Adelman RA. Hyperacuity Exam Screens for Choroidal Neovascularization in Age-Related Macular Degeneration on a Mobile Device. Ophthalmic Surgery Lasers And Imaging Retina 2016, 47: 708-15. PMID: 27548447, DOI: 10.3928/23258160-20160808-03.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChoroidChoroidal NeovascularizationComputers, HandheldCross-Sectional StudiesEquipment DesignFemaleFluorescein AngiographyFundus OculiHumansMacular DegenerationMaleMiddle AgedMobile ApplicationsMonitoring, PhysiologicReproducibility of ResultsTomography, Optical CoherenceVisual AcuityConceptsAge-related macular degenerationChoroidal neovascularizationMacular degenerationSpectral-domain optical coherence tomographySingle-center studyProgression of diseaseOptical coherence tomographyChart reviewTimely treatmentPatientsCoherence tomographyNeovascularizationPatient informationSame dayTreatmentPotential screenFurther dataHuman Research Protection ProgramDegenerationSubspecialistsDiseaseProgression
2012
Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up
Zebardast N, Adelman RA. Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up. Seminars In Ophthalmology 2012, 27: 61-64. PMID: 22784267, DOI: 10.3109/08820538.2012.680644.Peer-Reviewed Original ResearchConceptsChoroidal neovascularizationOptical coherence tomographyPseudoxanthoma elasticumFluorescein angiographyNeovascular activityTreatment of CNVIntravitreal ranibizumab injectionsFive yearsMacular choroidal neovascularizationLong-term effectivenessOCT evidenceIntravitreal ranibizumabRanibizumab injectionsRanibizumab therapyAffected eyeIntraretinal fluidVisual acuityFluorescein leakageAngioid streaksScar formationInitial injectionCoherence tomographyRanibizumabInjectionNeovascularization
2009
Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization
Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization. Investigative Ophthalmology & Visual Science 2009, 50: 3890-3896. PMID: 19357351, DOI: 10.1167/iovs.08-2833.Peer-Reviewed Original ResearchConceptsVisudyne photodynamic therapyChoroidal neovascularizationCNV lesionsTargeted photodynamic therapyDay 7Rat modelSafety of PDTPhotodynamic therapyOcular side effectsBrown Norway ratsFrequency of leakageFluorescein angiographyEfficacious doseHistopathologic evaluationLaser photocoagulationSide effectsFactor VIIDay 14LesionsNormal vasculatureRatsEndothelial cellsTherapyDoseNeovascularization
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
2007
Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis
Seth RK, Stoessel KM, Adelman RA. Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis. Seminars In Ophthalmology 2007, 22: 81-84. PMID: 17564926, DOI: 10.1080/08820530701418375.Peer-Reviewed Original ResearchConceptsWest Nile virus chorioretinitisChoroidal neovascularizationChoroidal Neovascularization AssociatedLate-onset complicationsBest therapeutic optionGood anatomical responseNeovascularization AssociatedDiabetes mellitusLeft eyeIntravitreal injectionTherapeutic optionsChorioretinitisNeovascularizationBevacizumabPatientsInjectionMellitusComplicationsBaseline